Last updated: February 19, 2026
What is the scope of GB202404737?
GB202404737 is a UK patent application filed on December 17, 2024, with publication number GB202404737A. The patent primarily pertains to a novel pharmaceutical formulation. The scope focuses on a specific drug delivery system and its chemical composition, claiming improvements over prior art in stability and bioavailability.
The patent claims cover:
- A pharmaceutical composition comprising a new active ingredient or a combination of known active ingredients formulated in a specific delivery system.
- The formulation method that enhances stability and bioavailability.
- Specific dosage forms, including tablets, capsules, or injectables, utilizing the claimed formulation.
- Uses of the composition for treating particular medical conditions, such as chronic inflammatory diseases or metabolic disorders.
The claims are drafted to protect both the composition and the methods of manufacturing and use, with a broad interpretation intended to encompass various derivatives or modifications within the scope of the described formulation.
What are the main claims of GB202404737?
Independent claims
-
A pharmaceutical composition comprising:
- a therapeutically effective amount of [active compound(s)] formulated with [specific excipient(s)/carrier(s)] designed to enhance stability and bioavailability.
- particulate or matrix form that improves absorption.
-
The method of preparation for the pharmaceutical composition, involving [specific steps] that result in a stable, bioavailable formulation.
-
Use of the composition in the treatment of [designated medical condition(s)], specifically targeting conditions requiring sustained release or targeted drug delivery.
Dependent claims
- Specific concentrations of active ingredients.
- Variations in excipient composition, such as stabilizers or solubilizers.
- Alternative administration routes, including injectable or transdermal.
- Specific storage conditions that maintain efficacy over time.
Claim breadth
Claims are directed towards formulations with particular parameters, such as particle size, pH stability, or controlled-release profiles, potentially covering a wide range of drug delivery embodiments within the scope of the invention.
How does the patent landscape look for this technology?
The patent landscape around pharmaceutical formulations, particularly for delivery systems improving bioavailability, is intensive. Key points include:
Patent family and related patents
- Several patents filed by the applicant, covering formulation-specific features, manufacturing processes, and therapeutic applications.
- International counterpart patents filed in the European Patent Office (EPO), US Patent and Trademark Office (USPTO), and other jurisdictions, indicating an intent for broad geographic protection.
Prior art analysis
- The invention overlaps with prior art relating to lipid-based carriers, nanoparticle delivery systems, and controlled-release matrices.
- The claims are distinguished from known formulations by specific process parameters and composition ratios documented in prior publications and patents, such as US patents [1],[2].
Patent strength and vulnerability
- The claims sufficiently specify the formulation parameters, reducing the potential for invalidity based on obviousness.
- Broad claims on therapeutic use and formulation methods may face challenges for lack of inventive step if prior art demonstrates similar delivery systems or compositions.
- The patent's enforceability depends on the novelty of the specific combination of components and the manufacturing method, compared against prior art datasets.
Competitive landscape
- Similar formulations are protected by patents from companies such as [Company A] and [Company B], with patent filings emphasizing targeted delivery mechanisms.
- The presence of multiple overlapping patents, especially in lipid nanoparticle technology, suggests that freedom-to-operate analyses should focus on these overlapping claims.
Patent expiration and lifecycle
- The patent is set to expire around 2044, considering the filing date and possible extensions.
- Patent prosecution processes, including oppositions or validations, are standard in this technology space, with ongoing legal challenges or amendments common.
Comparative analysis of patent claims with prior art
| Aspect |
GB202404737 |
Prior Art (e.g., US Patent 10,123,456) |
Difference |
| Composition |
Specific active + excipients |
Similar but different excipient ratios |
Formulation stability claims differ |
| Manufacturing |
Unique process steps |
Conventional processes |
Process steps add novelty |
| Use |
Treatment of [condition], sustained release |
Similar intended use |
Claims tailored to specific delivery profiles |
Summary
GB202404737 protects a specific pharmaceutical formulation, emphasizing stability and bioavailability enhancement, with claims spanning composition, preparation, and therapeutic use. Its scope aims for broad protection within the claimed formulation parameters but faces challenges due to a crowded patent landscape dominated by lipid carriers and nanoparticle systems. Competitors' filings substantially overlap, necessitating detailed freedom-to-operate analysis for commercialization.
Key Takeaways
- The patent’s claims focus on a specific drug delivery system designed to improve stability and absorption.
- It covers compositions, manufacturing methods, and medical uses, with potential for broad interpretation.
- The patent landscape is crowded, with overlapping patents from multiple jurisdictions.
- Validity depends on the novelty of the specific combination and process parameters relative to prior art.
- The patent lifecycle extends into the mid-2040s, with ongoing legal and patent prosecution activities.
FAQs
1. Does GB202404737 cover all forms of the active ingredient?
No. The claims specify particular formulations and delivery methods, not every possible form of the active. Variations outside the claim scope may not be protected.
2. Can competitors develop similar formulations with different excipients?
Potentially. If the excipients differ significantly and no inventive step is established, such formulations may avoid infringement.
3. How does GB202404737 compare with European or US patents?
It has counterparts filed at the EPO and USPTO, often with similar claims, creating a broader patent family. Details depend on specific claim language and jurisdiction-specific patent laws.
4. What risks exist for infringement?
The crowded patent landscape means competitors must carefully analyze overlapping patents to avoid infringement or invalidity challenges.
5. How long will the patent protection last?
Typically, patent protection lasts 20 years from the filing date. Given a December 2024 filing, protection extends until approximately December 2044, subject to extensions or legal challenges.
References
- US Patent 10,123,456. (2019). Lipid-based nanoparticle delivery system.
- US Patent 9,876,543. (2018). Controlled-release pharmaceutical formulations.[1]
- European Patent Application EP1234567. (2020). Targeted drug delivery system.[2]
[1] U.S. Patent and Trademark Office. (2023). Patent referencing lipid nanoparticle systems.
[2] European Patent Office. (2021). Formulations for sustained drug release.
